Celltrion | Sustainability Performance
Produces biosimilar drugs and therapeutic antibodies for global healthcare markets.
2002
South Korea
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#10519
Overallⓘ#157
in South Koreaⓘ#245
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Leading
Critical
Intensity
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
157.1
B/M 42.0
94.2
B/M 131.1
0.9
B/M 0.4
Powered by illuminem and GIST Impact
Controversy level
- Celltrion has faced periodic FDA Form 483 observations at its South Korean biologics manufacturing facilities affecting Remsima and other biosimilar production schedules and quality compliance concerns.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
1
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.